There are two serious side effects of anti-estrogen therapy. We've all heard about the difficult side effects of Tamoxifen. They range from discomforting to life-threatening. But, with all the talk among survivors, there are the most serious side effects and you should be worried.
Hello, my name’s Greg Doucette. I'm a master's degree in kinesiology. Today the topic is about what to do for PCT after you do SARS or steroid cycle. Before I explain that I want to point out that I'm not a doctor, but I’m talking about my experience. So, you can read it for entertainment.
In December 2012, when we were at the San Antonio Breast Cancer Symposium, we had discussed a story at San Antonio meeting, and it was about continuing Tamoxifen for another five years.
Welcome everyone. Today I’m going to talk about Nolvadex and all the facts around it. So, Nolvadex is the trade name for the drug Tamoxifen citrate. That was first manufactured by Imperial Chemical Industries. Later that was purchased by Astra Zeneca, and they are one of the largest pharmaceutical companies in the world. Currently Tamoxifen is on the World Health Organization's list of essential medicines.
I'd like to share with you the results of a similar study that we performed at a Leiden University Medical Center in the Netherlands, and I'll start off with a short introduction on Tamoxifen.
How to combat three common side-effects of Tamoxifen? You've gone through surgery. Now your doctor has you on Tamoxifen. And you've been experiencing side effects like hot flashes, nausea and mood swings. You understand that Tamoxifen reduces the risk of breast cancer recurrence, but you may be wondering if you can continue dealing with the side effects for full ten years.
The first one that was presented was the first presentation of an eagerly awaited trial looking at more than the usual five years of Tamoxifen. So, we have been using Tamoxifen as a hormonal therapy to lower the risk of recurrence after the treatment for early-stage breast cancer for several decades now.
Page: 1 from 4